Tsuji Yoshiko, Hara Tomoaki, Meng Sikun, Sato Hiromichi, Arao Yasuko, Ofusa Ken, Ishii Hideshi
Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Department of Gastrointestinal Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Oncol Lett. 2023 Jun 20;26(2):336. doi: 10.3892/ol.2023.13922. eCollection 2023 Aug.
Pancreatic cancer stem cells (CSCs) play a key role in the initiation and progression of pancreatic adenocarcinoma (PDAC). CSCs are responsible for resistance to chemotherapy and radiation, and for cancer metastasis. Recent studies have indicated that RNA methylation, a type of RNA modification, predominantly occurring as m6A methylation, plays an important role in controlling the stemness of cancer cells, therapeutic resistance against chemotherapy and radiation therapy, and their overall relevance to a patient's prognosis. CSCs regulate various behaviors of cancer through cell-cell communication by secreting factors, through their receptors, and through signal transduction. Recent studies have shown that RNA methylation is involved in the biology of the heterogeneity of PDAC. The present review provides an update on the current understanding of RNA modification-based therapeutic targets against deleterious PDAC. Several key pathways and agents that can specifically target CSCs have been identified, thus providing novel insights into the early diagnosis and efficient treatment of PDAC.
胰腺癌干细胞(CSCs)在胰腺腺癌(PDAC)的发生和发展中起关键作用。CSCs对化疗和放疗具有抗性,并与癌症转移有关。最近的研究表明,RNA甲基化作为一种RNA修饰,主要以m6A甲基化的形式存在,在控制癌细胞的干性、对化疗和放疗的治疗抗性以及它们与患者预后的整体相关性方面发挥着重要作用。CSCs通过分泌因子、通过其受体以及通过信号转导,通过细胞间通讯来调节癌症的各种行为。最近的研究表明,RNA甲基化参与了PDAC异质性的生物学过程。本综述提供了关于基于RNA修饰的针对有害PDAC的治疗靶点的当前理解的最新情况。已经确定了几种可以特异性靶向CSCs的关键途径和药物,从而为PDAC的早期诊断和有效治疗提供了新的见解。